Physician profile
Naveen Bellam
NPI 1619260239
$413,923.40
in general payments reported to CMS, 2019-2025
31 companies · $100K in 2025
The $100K reported for 2025 was more than what 97% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $11K · 2021: $23K · 2022: $62K · 2023: $117K · 2024: $100K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Travel and Lodging: $53K · Honoraria: $13K · Food and Beverage: $12K · Consulting Fee: $7,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,891.22 |
| Travel and Lodging | $53,137.55 |
| Honoraria | $12,800.00 |
| Food and Beverage | $12,095.71 |
| Consulting Fee | $7,875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $250,123.91 | 2019-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $99,423.39 | 2022-2024 | Verquvo |
| Bridgebio Pharma, INC. | $30,637.14 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $18,531.45 | 2022-2025 | Optimizer, Optimizer |
| Pfizer INC. | $10,948.71 | 2019-2025 | |
| Abbott Laboratories | $1,218.75 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Cvrx, INC. | $840.35 | 2022-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $218.63 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $201.28 | 2023-2024 | Assure Wcd |
| Abiomed | $176.16 | 2024-2025 | Impella |
| Boston Scientific Corporation | $147.40 | 2023 | Watchman Access System |
| Daxor Corporation | $144.50 | 2024 | Bva-100 |
| Akcea Therapeutics, INC. | $137.51 | 2019 | |
| United Therapeutics Corporation | $133.51 | 2019 | |
| Nuwellis, INC. | $128.32 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2023 | Livtencity |
| Novo Nordisk INC | $111.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.85 | 2022-2023 | Jardiance |
| American Regent | $98.06 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $95.86 | 2022-2025 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $53.13 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.33 | 2022-2024 | Lifevest |
| Cardiac Dimensions, INC. | $52.16 | 2023-2024 | |
| Scpharmaceuticals INC. | $44.43 | 2024-2025 | |
| Eurofins Viracor, LLC | $36.60 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $30.20 | 2019 | |
| Genzyme Corporation | $29.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.08 | 2025 | |
| Briohealth Solutions, INC. | $21.57 | 2025 | Briovad |
| Janssen Pharmaceuticals, INC | $18.61 | 2021 | |
| Daiichi Sankyo INC. | $17.16 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Bellam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.